Key Highlights

  • GPs using MedicalDirector can order ColoSTAT directly from their practice software, live since 1 August 2026.
  • The 4Cyte Pathology collection network passed 100 sites, up from 78 at the end of March 2026.
  • Cash at 30 September 2026 was $1.8 million, with net operating cash outflow of $1.47 million for the quarter.
  • The new geneType lung cancer risk test identified 42% more cases eligible for screening than current Australian criteria.

Rhythm Biosciences Ltd (ASX:RHY), a precision diagnostics company focused on earlier cancer detection and personalised risk assessment, released its Quarterly Activities Report and Appendix 4C for the quarter from 1 July to 30 September 2026 on 27 October 2026.

ColoSTAT Access and Regulatory Steps

The company said GPs can now order its ColoSTAT blood test from within MedicalDirector, one of the most widely used GP software systems in Australia. The 4Cyte Pathology blood collection network passed 100 sites across the eastern states, and the Access Program, designed to collect real-world evidence, now includes 19 clinicians.

ColoSTAT was accepted into the TGA In-House IVD Notification Database for testing in Rhythm’s NATA-accredited laboratory. An independent health economic study by Value-Based Access modelled the potential benefits to the public health system of using ColoSTAT to decide who needs a colonoscopy, which the company described as a building block for a potential Medicare reimbursement application. In England, a technology transfer now enables the NHS laboratory to run ColoSTAT, with testing of patient samples as the next step.

geneType, Board Changes and Cash

Rhythm’s new geneType lung cancer risk test found 42% more lung cancer cases eligible for screening than current Australian criteria. The first phase of an independent review of US reimbursement for geneType was completed, identifying potential pathways. Two new non-executive directors joined the Board, and an interim Chair was appointed following the resignation of the previous Chair.

Cash at 30 September 2026 was $1.8 million. Net cash used in operating activities was $1.47 million, with receipts from customers of $36,000 and research and development payments of $654,000. The company expects to lodge its FY26 Research and Development Tax Incentive claim, and its next-quarter milestones include launching ColoSTAT ordering in Best Practice software.

Why This Could Matter

The report sets out progress on distribution, evidence and reimbursement planning for a test that is at an early commercial stage. Customer receipts of $36,000 compare with operating outflows of $1.47 million for the quarter, which shows where the company sits in that process.

Final Takeaway

Rhythm reported wider GP ordering and collection access, regulatory and health economic milestones, and a lung cancer risk test. Customer receipts remain small relative to quarterly spending, and Medicare reimbursement is described as a potential next step.